[Efficacy and safety of levofloxacin in low respiratory tract infection].
Zubkov
M N
MN
D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D002493:Central Nervous System Diseases / Q000139:chemically induced; D002986:Clinical Trials as Topic; D003876:Dermatitis, Atopic / Q000139:chemically induced; D005767:Gastrointestinal Diseases / Q000139:chemically induced; D006090:Gram-Negative Bacteria / Q000187:drug effects; D006095:Gram-Positive Cocci / Q000187:drug effects; D006801:Humans; D064704:Levofloxacin; D008826:Microbial Sensitivity Tests; D015242:Ofloxacin / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D011018:Pneumonia, Pneumococcal / Q000188:drug therapy; D012141:Respiratory Tract Infections / Q000188:drug therapy* / Q000382:microbiology; D013296:Streptococcus pneumoniae / Q000187:drug effects
D000900:Anti-Bacterial Agents; D064704:Levofloxacin; D015242:Ofloxacin